| 8.13 -0.277 (-3.29%) | 07-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.24 | 1-year : | 11.96 |
| Resists | First : | 8.76 | Second : | 10.24 |
| Pivot price | 7.73  |
|||
| Supports | First : | 7.58 | Second : | 6.84 |
| MAs | MA(5) : | 8.21 |
MA(20) : | 7.64 |
| MA(100) : | 6.65 |
MA(250) : | 6.6 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 73.8 |
D(3) : | 71 |
| RSI | RSI(14): 59.3 |
|||
| 52-week | High : | 16.5 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SLGL ] has closed below upper band by 27.9%. Bollinger Bands are 12.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.41 - 8.45 | 8.45 - 8.49 |
| Low: | 7.88 - 7.93 | 7.93 - 7.97 |
| Close: | 8.05 - 8.13 | 8.13 - 8.2 |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Wed, 07 May 2025
Will Sol-Gel Deliver The First Preventive Treatment For Gorlin Syndrome? - RTTNews
Mon, 05 May 2025
Sol-Gel Technologies Announces Reverse Share Split to Regain Nasdaq Compliance - TipRanks
Thu, 01 May 2025
Sol-Gel Sets 10:1 Reverse Split: Key Details About Share Consolidation and Nasdaq Compliance Plan - Stock Titan
Tue, 18 Feb 2025
Sol-Gel Technologies Schedules Shareholder Meeting to Vote on Key Proposals - TipRanks
Wed, 20 Nov 2024
SolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should Know - Nasdaq
Tue, 26 Mar 2024
SLGL Stock Quote Price and Forecast - CNN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 70 (%) |
| Held by Institutions | 24.2 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 15 (K) |
| EPS | -4.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.23 |
| Profit Margin | -107.8 % |
| Operating Margin | -879.7 % |
| Return on Assets (ttm) | -26.9 % |
| Return on Equity (ttm) | -49.4 % |
| Qtrly Rev. Growth | 121.1 % |
| Gross Profit (p.s.) | -3.3 |
| Sales Per Share | 4.33 |
| EBITDA (p.s.) | -5.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -1.73 |
| PEG Ratio | 0 |
| Price to Book value | 1.12 |
| Price to Sales | 1.87 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|